Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02608268
Title Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

renal cell carcinoma

lung non-small cell carcinoma

melanoma

Advanced Solid Tumor

Therapies

Spartalizumab

Sabatolimab

Age Groups: adult
Covered Countries USA | ITA | CAN


No variant requirements are available.